Accretion Pharmaceuticals IPO

NSDL, India’s pioneering depository, combines institutional dominance with robust digital public infrastructure capabilities. As it approaches listing, its strengths in high-margin revenues and regulatory trust are offset by retail underpenetration and emerging fintech threats.

NSDL’s pre-IPO grey-market valuation implies a 63.3× trailing P/E, but actual listing prices could swing widely depending on investor confidence, regulatory clarity, and execution on digital and banking ventures. Scenario modeling across 55× to 75× forward P/E multiples shows a potential price range of ₹1,103–₹1,504, offering a roadmap for assessing risk-adjusted upside.

NSDL’s rich unlisted valuation reflects its institutional edge, digital infrastructure revenues, and upside from its Payments Bank, but post-IPO, some premium may normalize. With CDSL riding strong retail growth and expanding fintech partnerships, the valuation gap could narrow as earnings converge over FY26–27.